Skip to content
For laboratory research use only · Not for human or veterinary use · Qualified buyers only
Peptides

Tirzepatide: Dual GIP/GLP-1 Agonist Identity and Laboratory Documentation

A research-use identity note on tirzepatide as a dual GIP/GLP-1 agonist, with attributed published findings and lot-documentation notes.

Tirzepatide: Dual GIP/GLP-1 Agonist Identity and Laboratory Documentation

Tirzepatide is a modified peptide designed to activate both GIP and GLP-1 receptors in metabolic-signaling research. The original overview of this page asks three questions: dual-receptor agonist design, receptor-selective assay interpretation, and identity, content, purity, and aggregation for the lot on the bench.

Editorial review: 17 November 2026. Prepared by Velnacor Research Desk for research-use communication only. Published findings below are attributed to the cited papers. They are not claims about a Velnacor lot and are not instructions for use in people or animals.

Dual GIP/GLP-1 agonist identity

Coskun and colleagues described LY3298176 as a fatty-acid-modified peptide with dual glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1) receptor agonist activity. In vitro it activated both receptor-signaling pathways; in mice it improved glucose tolerance by acting on both receptors and, with chronic administration, decreased body weight and food intake to a greater extent than a GLP-1-receptor agonist in the comparison they reported (Coskun et al., 2018). Jastreboff and colleagues later identified tirzepatide as a GIP and GLP-1 receptor agonist in a phase 3 obesity trial (Jastreboff et al., 2022). Tirzepatide is not semaglutide, a selective GLP-1 analogue, and it is not retatrutide, which also engages the glucagon receptor. See Semaglutide: GLP-1-Analogue Identity, Sequence Modifications, and Laboratory Documentation, What Is Retatrutide?, and Retatrutide vs Tirzepatide.

A dual-agonist label is not a substitute for the exact analogue name, content, and aggregation status on the report.

Published clinical-research observations — and their limits

In the SURMOUNT-1 trial, Jastreboff and colleagues randomly assigned 2,539 adults with a BMI of 30 or more, or 27 or more plus at least one weight-related complication, excluding diabetes, to once-weekly tirzepatide or placebo for 72 weeks. They reported mean body-weight changes at week 72 of −15.0%, −19.5%, and −20.9% in the tirzepatide dose groups they studied, compared with −3.1% with placebo (Jastreboff et al., 2022).

In SURPASS-2, Frías and colleagues compared once-weekly tirzepatide with once-weekly semaglutide in a 40-week, open-label, phase 3 trial in type 2 diabetes and reported that tirzepatide was noninferior and superior to semaglutide for the mean change in glycated hemoglobin from baseline to week 40 (Frías et al., 2021). That comparison belongs to those two analogues in that population. It is not a head-to-head with retatrutide, and it is not a laboratory protocol.

Those papers are published clinical-research findings. They are not administration or dosing guidance, and they do not describe a current catalog lot. Percentages and dose-group labels are transcribed only as the authors reported them.

Identity, content, purity, and aggregation

Receptor-selective assays should name the analogue under test. Purity, content, and aggregation are separate questions. What Is a Peptide COA?, How to Read a Peptide COA, HPLC vs Mass Spectrometry for Peptide Lot Review, Third-Party Peptide Testing, Explained, and lot traceability apply independently to this row.

Tirzepatide appears in Velnacor’s research-material catalog (internal product record, slug tirzepatide), as does a combination SKU with retatrutide. There is not a standalone public landing page for every catalog name; use the product directory and the COA Library, then confirm the exact SKU and current-lot documents in the inquiry. Combination presentations, if purchased, need their own identifiers. For packing at supply scale, see wholesale peptides.

Selected published literature

  1. Coskun T, Sloop KW, Loghin C, Alsina-Fernandez J, Urva S, Bokvist KB, Cui X, Briere DA, Cabrera O, Roell WC, Kuchibhotla U, Moyers JS, Benson CT, Gimeno RE, D’Alessio DA, Haupt A. LY3298176, a novel dual GIP and GLP-1 receptor agonist for the treatment of type 2 diabetes mellitus: from discovery to clinical proof of concept. Molecular Metabolism. 2018;18:3-14. doi:10.1016/j.molmet.2018.09.009. PubMed 30473097.
  2. Jastreboff AM, Aronne LJ, Ahmad NN, Wharton S, Connery L, Alves B, Kiyosue A, Zhang S, Liu B, Bunck MC, Stefanski A; SURMOUNT-1 Investigators. Tirzepatide once weekly for the treatment of obesity. New England Journal of Medicine. 2022;387(3):205-216. doi:10.1056/NEJMoa2206038. PubMed 35658024. Cited as published clinical-research observations, not as a use instruction.
  3. Frías JP, Davies MJ, Rosenstock J, Pérez Manghi FC, Fernández Landó L, Bergman BK, Liu B, Cui X, Brown K; SURPASS-2 Investigators. Tirzepatide versus semaglutide once weekly in patients with type 2 diabetes. New England Journal of Medicine. 2021;385(6):503-515. doi:10.1056/NEJMoa2107519. PubMed 34170647. Cited as published clinical-research observations, not as a use instruction.

Sourcing notes for qualified buyers

Velnacor’s stated supply terms for qualified research and business buyers include: every batch is third-party tested; orders usually ship within 24 hours, subject to stock, documentation review, and destination; trial orders can start from one box of ten vials; parcels lost or damaged in transit are eligible for free reshipment or a refund; and neutral packaging is available when required. Velnacor operates its own production base and has a long-standing supply-chain business.

Those points describe documentation and fulfillment. They do not describe a laboratory or biological outcome. For an order-specific review, send the material name, specification, box quantity, and destination through the inquiry list.

Research-use notice. All Velnacor products are intended strictly for laboratory research use only. They are not drugs, supplements, or food, and are not intended to diagnose, treat, cure, or prevent any disease. Not for human or veterinary use. Purchasers must be qualified researchers. This article is educational content for laboratory and business readers. It does not provide dosing, reconstitution, administration, diagnostic, or treatment guidance.

My inquiry listNo products added yet0